Patent · US Active

Vidofludimus for use in the treatment or prevention of viral diseases

US11376232B2 · kind B2 · utility

1Cited by

5References

29Claims

0Family size

Assignee

IMMUNIC AG · DE

Inventors

Manfred GRÖPPEL · Erlangen, DE
Daniel VITT · Germering, DE
Hella KOHLHOF · Munich, DE
Andreas Muhler · Oderberg, DE

Key dates

Filing date	Apr 20, 2021
Grant date	Jul 5, 2022
Priority date	—
Expiry date	Apr 20, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a compound according to Formula (I) or a salt, solvate and/or a hydrate thereof, wherein said compound inhibits dihydroorotate dehydrogenase (DHODH), for use in the treatment and prevention of viral infection. A preferred example is viral infection caused by coronavirus, in particular betacoronavirus, more particular SARS-CoV-2 and mutated versions thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.